Leerink Partners Assumes Pliant Therapeutics at Outperform, Announces Price Target of $33
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has assumed coverage of Pliant Therapeutics with an Outperform rating and set a price target of $33.
September 09, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Leerink Partners has assumed coverage of Pliant Therapeutics with an Outperform rating and set a price target of $33, indicating a positive outlook.
The Outperform rating and a price target of $33 from Leerink Partners suggest a positive outlook for Pliant Therapeutics, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100